Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996608 | 0.87 | CNR2 (0.49) | CNR2ESR1ESR2CNR1 | |
| SCHEMBL23616384 | 0.84 | CNR2 (0.44) | CNR2ESR1ESR2CNR1NPC1 | |
| SCHEMBL25101398 | 0.82 | ESR1 (0.48) | ESR1ESR2MEN1NPC1MAPT | |
| SCHEMBL19987501 | 0.82 | CNR2 (0.42) | CNR2ESR1ESR2MEN1KMT2A | |
| SCHEMBL780298 | 0.81 | NPC1 (0.48) | CNR2MEN1NPC1MAPTXBP1 | |
| SCHEMBL18930278 | 0.81 | TSHR (0.46) | CNR2ESR1ESR2CNR1AR | |
| SCHEMBL14039798 | 0.80 | CNR2 (0.38) | CNR2NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL5777587 | 0.80 | SMN1; SMN2 (0.39) | CNR2ESR1ESR2CNR1MEN1 | |
| SCHEMBL19441058 | 0.80 | TAAR1 (0.50) | ESR1ESR2MEN1MAPK1HTT | |
| SCHEMBL12981405 | 0.79 | TSHR (0.50) | CNR2ESR1ESR2CNR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AMGEN INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11180498-B2 | Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-23 | — | — | US | disclosed |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190144416-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-16 | — | — | US | disclosed |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180194757-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9987276-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-06-05 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654137-B2 | 3-(hydroxy)-pyridin-4(1H)-one compounds and methods of making and using the same | KDM1B, KDM3A, KDM1A | CNR2 4503/4885ESR1 2792/4885ESR2 2168/4885 |
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | CNR2 1429/4885ESR1 3722/4885ESR2 2856/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | CNR2 1209/4885ESR1 4268/4885ESR2 2809/4885 |
| US-20180194757-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CNR2 1057/4885ESR1 3109/4885ESR2 3276/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | CNR2 3026/4885ESR1 4768/4885ESR2 4317/4885 |
| US-20190144416-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | CNR2 474/4885ESR1 3732/4885ESR2 2060/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | CNR2 1429/4885ESR1 3722/4885ESR2 2856/4885 |
| US-11191762-B2 | Alkyl substituted triazole compounds as agonists of the APJ Receptor | AGTR1, AGTR2, APLNR | CNR2 175/4885ESR1 1529/4885ESR2 882/4885 |
| US-11649251-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | CNR2 4601/4885ESR1 1941/4885ESR2 2279/4885 |
| US-11180498-B2 | Substituted pyrrolo[2,3-b]pyridines, pyrazolo[3,4-d]pyrimidines and [1,2,3]triazolo[4,5-b]pyridines as potent antivirals | PNPO, TYMS, TYMP | CNR2 3148/4885ESR1 4715/4885ESR2 4311/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | CNR2 2355/4885ESR1 3161/4885ESR2 3084/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | CNR2 181/4885ESR1 2396/4885ESR2 1986/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CNR2 3006/4885ESR1 2409/4885ESR2 1922/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | CNR2 528/4885ESR1 2700/4885ESR2 1201/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CNR2 4097/4885ESR1 1884/4885ESR2 2708/4885 |
| US-20190119216-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | CNR2 474/4885ESR1 3732/4885ESR2 2060/4885 |
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | CNR2 3923/4885ESR1 4809/4885ESR2 4115/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | CNR2 528/4885ESR1 2700/4885ESR2 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.